16.65

1.75% -0.268

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $16.65, with a volume of 795.01K. It is down -1.75% in the last 24 hours and down -9.11% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Previous Close:

$16.92

Open:

$16.9

24h Volume:

795.01K

Relative Volume:

0.29

Market Cap:

$4.00B

Revenue:

$382.81M

Net Income/Loss:

$68.13M

P/E Ratio:

59.47

EPS:

0.28

Net Cash Flow:

$78.82M

1W Performance:

+2.93%

1M Performance:

-9.11%

6M Performance:

+45.19%

1Y Performance:

+220.93%

1-Day Range:

$16.57

$17.06

1-Week Range:

$15.70

$17.20

52-Week Range:

$5.02

$23.64

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

624

Twitter

@AdmaBiologics

Next Earnings Date

2024-12-07

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	16.65	4.00B	382.81M	68.13M	78.82M	0.28
VRTX Vertex Pharmaceuticals Inc	473.20	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.22	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.00	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.74	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.25	28.75B	3.30B	-501.07M	1.03B	-2.1146

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

12:54 PM

ADMA Loses 8.9% in a Month: How Should You Play the Stock? - Zacks Investment Research

12:54 PM

Feb 06, 2025

Adma Biologics (ADMA) Advances But Underperforms Market: Key Facts - MSN

Feb 06, 2025

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add (NASDAQ:ADMA) - Seeking Alpha

Feb 06, 2025

Feb 05, 2025

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Feb 05, 2025

Feb 04, 2025

Engaging In Insider Activity, Kaitlin M. Kestenberg-Messina At ADMA Biologics Exercises Options Worth $28K - Benzinga

Feb 04, 2025

Will Weakness in ADMA Biologics, Inc.'s (NASDAQ:ADMA) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St

Feb 04, 2025

Feb 02, 2025

Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Increases By 11.8% - MarketBeat

Feb 02, 2025

Jan 30, 2025

Jim Cramer on ADMA Biologics, Inc. (ADMA): ‘I Would Wait For It To Come Down Before I Would Pull The Trigger’ - Insider Monkey

Jan 30, 2025

8 Stocks on Jim Cramer’s Radar - Insider Monkey

Jan 30, 2025

Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Benzinga

Jan 30, 2025

Where are the Opportunities in (ADMA) - Stock Traders Daily

Jan 30, 2025

Jan 28, 2025

Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Jan 28, 2025

Jan 26, 2025

ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Inspire Investing LLC - MarketBeat

Jan 26, 2025

Jan 24, 2025

Veracity Capital LLC Boosts Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Jan 24, 2025

Jan 23, 2025

ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corp - Reuters

Jan 23, 2025

Jan 22, 2025

Perpetual Ltd Acquires Shares of 3,632,677 ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Jan 21, 2025

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? - MSN

Jan 21, 2025

Jan 20, 2025

Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News

Jan 20, 2025

There May Still Be Time to Get in on These 3 Trending Biotechs - MarketBeat

Jan 20, 2025

Sana Biotechnology Inc (SANA-Q) QuotePress Release - The Globe and Mail

Jan 20, 2025

Jan 19, 2025

How the (ADMA) price action is used to our Advantage - Stock Traders Daily

Jan 19, 2025

Assenagon Asset Management S.A. Sells 2,882,776 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World

Jan 19, 2025

Jan 18, 2025